Global Circulating Tumor Cells Prognostic Technologies Market Analysis: Technologies, Applications and Forecast to 2020, New Research Study by iHealthcareAnalyst, Inc.
Circulating Tumor Cells Prognostic Technologies Market by Technology (Tumor Cell Enrichment, Centrifugation, Filtration, Immunological Methods, Tumor Cell Detection, Molecular Methods, Optical Methods), and Application (Breast Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer and Pancreatic Cancer) 2016-2020
Maryland Heights, MO, January 27, 2017 --(PR.com)-- The global circulating tumor cells prognostic technologies market to reach nearly USD 1.9 Billion in 2020, at a CAGR of 18.9% from 2016 to 2020, due to higher prevalence of various cancers worldwide and awareness about the availability of personalized medicines. By technology, tumor cell detection and by application, colon cancer segments contributed to the largest share of the global circulating tumor cells prognostic technologies market. By geography, North America dominated the overall global market followed by Europe and Asia Pacific region.
Browse Circulating Tumor Cells Prognostic Technologies Market by Technology (Tumor Cell Enrichment, Centrifugation, Filtration, Immunological Methods, Tumor Cell Detection, Molecular Methods, Optical Methods), and Application (Breast Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer and Pancreatic Cancer) 2016-2020 at https://www.ihealthcareanalyst.com/report/circulating-tumor-cells-prognostic-technologies-market/
Circulating tumor cells (CTCs) are promising circulating biomarkers, and novel technologies are underway to overcome some of the specific challenges to fully harness the clinical potential of these circulating biomarkers. Circulating tumor cells can be detected in the circulation, where the detection of CTCs in blood can provide prognostic information. Advanced technologies emerge to characterize CTCs at the molecular level, where the biological information can be obtained in real time. CTCs have been identified in many different cancers. There is a great potential of CTCs to be used as pharmacodynamics and predictive biomarkers and potentially their use in revealing drug resistance in real time. Monitoring CTCs predicts the metastatic tumor progression in prostate, breast, colorectal, lung, ovarian and pancreatic cancer.
The global circulating tumor cells prognostic technologies market segmentation is based on technology tumor cell enrichment, centrifugation, filtration, immunological methods, tumor cell detection, molecular methods, optical methods), and its application (breast cancer, colorectal cancer, prostate cancer, lung cancer, ovarian cancer and pancreatic cancer, etc.).
The global circulating tumor cells prognostic technologies market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global circulating tumor cells prognostic technologies market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global circulating tumor cells prognostic technologies market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global circulating tumor cells prognostic technologies market and included in this report are AdnaGen AG, Advanced Cell Diagnostics, Inc., AVIVA BioSciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., Veridex, LLC, and Vitatex, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/circulating-tumor-cells-prognostic-technologies-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse Circulating Tumor Cells Prognostic Technologies Market by Technology (Tumor Cell Enrichment, Centrifugation, Filtration, Immunological Methods, Tumor Cell Detection, Molecular Methods, Optical Methods), and Application (Breast Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer and Pancreatic Cancer) 2016-2020 at https://www.ihealthcareanalyst.com/report/circulating-tumor-cells-prognostic-technologies-market/
Circulating tumor cells (CTCs) are promising circulating biomarkers, and novel technologies are underway to overcome some of the specific challenges to fully harness the clinical potential of these circulating biomarkers. Circulating tumor cells can be detected in the circulation, where the detection of CTCs in blood can provide prognostic information. Advanced technologies emerge to characterize CTCs at the molecular level, where the biological information can be obtained in real time. CTCs have been identified in many different cancers. There is a great potential of CTCs to be used as pharmacodynamics and predictive biomarkers and potentially their use in revealing drug resistance in real time. Monitoring CTCs predicts the metastatic tumor progression in prostate, breast, colorectal, lung, ovarian and pancreatic cancer.
The global circulating tumor cells prognostic technologies market segmentation is based on technology tumor cell enrichment, centrifugation, filtration, immunological methods, tumor cell detection, molecular methods, optical methods), and its application (breast cancer, colorectal cancer, prostate cancer, lung cancer, ovarian cancer and pancreatic cancer, etc.).
The global circulating tumor cells prognostic technologies market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global circulating tumor cells prognostic technologies market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global circulating tumor cells prognostic technologies market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global circulating tumor cells prognostic technologies market and included in this report are AdnaGen AG, Advanced Cell Diagnostics, Inc., AVIVA BioSciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., Veridex, LLC, and Vitatex, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/circulating-tumor-cells-prognostic-technologies-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories